A population-based retrospective cohort study
Rates of opioid use disorder (OUD) have been rising and has led to accelerated rates of opioid-related deaths. Opioid agonist therapy (OAT) with methadone or buprenorphine/naloxone is an effective treatment option for people with OUD. OAT prevents opioid withdrawal, manages cravings, and lowers the risk of fatal overdose and opioid-related emergency care compared to other treatments.
This study examined treatment duration among people initiating methadone or buprenorphine/naloxone in Ontario, Canada, and whether retention varies according to age, sex, and urban/rural residence.
Access the full article: